# Open Label Trial to Explore Safety of Combining Afatinib (BIBW 2992) and Radiotherapy With or Without Temozolomide in Newly Diagnosed Glioblastoma Multiform

> **NCT00977431** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 36 (actual)

## Conditions studied

- Glioblastoma

## Interventions

- **DRUG:** Temozolomide
- **PROCEDURE:** Radiotherapy
- **DRUG:** BIBW2992
- **PROCEDURE:** Radiotherapy
- **DRUG:** BIBW2992

## Key facts

- **NCT ID:** NCT00977431
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09-17
- **Primary completion:** 2017-09-12
- **Final completion:** 2017-09-12
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2019-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00977431

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00977431, "Open Label Trial to Explore Safety of Combining Afatinib (BIBW 2992) and Radiotherapy With or Without Temozolomide in Newly Diagnosed Glioblastoma Multiform". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00977431. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*